BICYCLE THERAPEUTICS PLC

Bicycle Therapeutics is a clinical-stage biotechnology company developing a proprietary class of medicines called bicycle toxin conjugates (BTCs) and related molecules designed to target cancers and other diseases with limited existing treatment options. The company's lead program, zelenectide pevedotin, is in phase I/II/III clinical trials for tumors expressing high levels of nectin-4. Additional programs in clinical development include BT5528, a BTC targeting EphA2-expressing tumors in phase I/II trials, and BT7480, a tumor-targeted immune cell agonist molecule also in phase I/II development. The company maintains a preclinical pipeline targeting central nervous system diseases, neuromuscular disorders, and radiopharmaceutical applications.

Bicycle Therapeutics operates primarily through research and development activities with no disclosed revenue streams from marketed products. The company has established collaboration and licensing agreements with major pharmaceutical partners including Novartis, Bayer, Genentech, and Ionis Pharmaceuticals to advance its therapeutic programs. Headquartered in Cambridge, United Kingdom, the company employs approximately 305 full-time staff and is listed on Nasdaq with a market capitalization of $0.4 billion.